ZINBRYTA
Biological
Biogen, Inc.
Total Payments
$2.8M
Transactions
3,136
Doctors
905
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $32,985 | 3 | 2 |
| 2019 | $42,086 | 9 | 1 |
| 2018 | $583,494 | 460 | 126 |
| 2017 | $2.1M | 2,664 | 841 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.5M | 707 | 53.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $902,625 | 367 | 32.3% |
| Consulting Fee | $226,695 | 270 | 8.1% |
| Travel and Lodging | $113,749 | 384 | 4.1% |
| Food and Beverage | $51,861 | 1,376 | 1.9% |
| Education | $548.48 | 32 | 0.0% |
Payments by Type
Research
$1.5M
707 transactions
General
$1.3M
2,429 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 | Biogen, Inc. | $714,221 | 2 |
| Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab | Biogen, Inc. | $610,242 | 5 |
| The Role of Daclizumab on progression of disease through interaction with Oligodendrocyte Precursor Cells. | Biogen, Inc. | $148,783 | 0 |
| An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis | Biogen, Inc. | $15,225 | 0 |
| Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon 1a in Participants With Relapsing-Remitting Multiple Sclerosis | Biogen, Inc. | $12,540 | 4 |
Top Doctors Receiving Payments for ZINBRYTA — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Neurology | Freehold, NJ | $11,822 | 11 |
| , MD | Neurology | Hattiesburg, MS | $11,318 | 13 |
| , MD | Neurology | Westerville, OH | $10,596 | 5 |
| Douglas Jeffery | — | Huntersville, NC | $10,544 | 13 |
| , MD | Gastroenterology | Manhasset, NY | $10,045 | 8 |
| Andrew Woo | — | Santa Monica, CA | $9,707 | 8 |
| , MD | Anesthesiology | Pinehurst, NC | $9,540 | 18 |
| , MD | Clinical Neurophysiology | Gilbert, AZ | $9,408 | 11 |
| , MD, PHD | Dermatology | New York, NY | $9,253 | 7 |
| , MD | Neurology | Melbourne, FL | $9,037 | 19 |
| , M.D | Neurology | Staten Island, NY | $8,551 | 12 |
| , D.O | Neurology | Baltimore, MD | $8,288 | 5 |
| , MD | Neurology | Medford, OR | $7,859 | 10 |
| , MD | Neurology | Norwich, CT | $7,675 | 9 |
| , MD | Pediatrics | Manassas, VA | $7,637 | 9 |
| , D.O | Neurology | Phoenix, AZ | $7,456 | 12 |
| , MD | Pulmonary Disease | Albany, NY | $7,394 | 3 |
| , M.D | Neurology | Atlanta, GA | $7,244 | 7 |
| , M.D | Neurology | Salt Lake Cty, UT | $7,168 | 6 |
| Sunita Tummala | Neurology | Flint, MI | $7,112 | 7 |
| , DO | Vascular Neurology | Ocala, FL | $6,930 | 24 |
| , MD | Neurology | Brighton, MA | $6,613 | 4 |
| , MD | Dermatology | Saint Louis, MO | $6,075 | 3 |
| , MD | Neurology | Mobile, AL | $6,007 | 6 |
| , MD | Neurology | Winston Salem, NC | $5,924 | 8 |
Ad
Manufacturing Companies
- Biogen, Inc. $2.8M
Product Information
- Type Biological
- Total Payments $2.8M
- Total Doctors 905
- Transactions 3,136
About ZINBRYTA
ZINBRYTA is a biological associated with $2.8M in payments to 905 healthcare providers, recorded across 3,136 transactions in the CMS Open Payments database. The primary manufacturer is Biogen, Inc..
Payment data is available from 2017 to 2020. In 2020, $32,985 was paid across 3 transactions to 2 doctors.
The most common payment nature for ZINBRYTA is "Unspecified" ($1.5M, 53.7% of total).
ZINBRYTA is associated with 5 research studies, including "Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019" ($714,221).